Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development

Abstract Background Plasmodium falciparum is the most influential species of malaria parasites, capable of causing severe illness and mortality, especially in pregnant women and children under the age of 5. Global distribution of disease impacted on billions of endemic people and travellers. Asexual...

Full description

Saved in:
Bibliographic Details
Main Authors: Gamolthip Niramolyanun, Chonnipa Praikongkatham, Rachaneeporn Jenwithisuk, Wanlapa Roobsoong, Jetsumon Sattabongkot, Viriya Pankao, Niwat Kangwanrangsan
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Malaria Journal
Subjects:
Online Access:https://doi.org/10.1186/s12936-025-05518-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849226572169478144
author Gamolthip Niramolyanun
Chonnipa Praikongkatham
Rachaneeporn Jenwithisuk
Wanlapa Roobsoong
Jetsumon Sattabongkot
Viriya Pankao
Niwat Kangwanrangsan
author_facet Gamolthip Niramolyanun
Chonnipa Praikongkatham
Rachaneeporn Jenwithisuk
Wanlapa Roobsoong
Jetsumon Sattabongkot
Viriya Pankao
Niwat Kangwanrangsan
author_sort Gamolthip Niramolyanun
collection DOAJ
description Abstract Background Plasmodium falciparum is the most influential species of malaria parasites, capable of causing severe illness and mortality, especially in pregnant women and children under the age of 5. Global distribution of disease impacted on billions of endemic people and travellers. Asexual stage and gametocyte cause harmful manifestations, impacting the patients and contributing to the spread of the disease in the community, respectively. Moreover, most recent therapeutic drugs did not affect the gametocyte. The discovery of a new drug with dual actions on both stages could elucidate a cost-effective way to combat malaria. Within a human host, the parasite possesses many activities for its survival, such as invasion, egress, haemoglobin degradation, and protein trafficking, many of which are related to aspartyl protease, revealing the potential for antimalarial drug targets. Methods Pepstatin A, the representative of the board-spectrum aspartyl protease inhibitor, was utilized to investigate the effects of aspartyl protease inhibition on parasite development. The experiments were separately performed in vitro for different developmental stages of parasites, including the asexual blood-stage, early gametocytes, late gametocytes, and gamete. To demonstrate the effects of pepstatin A, the number of intact parasites and their stage distribution were counted under the microscope and calculated as a percentage of inhibition compared to the control. Additionally, the morphology of pepstatin A-treated parasites was observed to identify cellular alterations in the parasites. Results Pepstatin A at 100 µM inhibited the asexual stage and early-stage gametocyte development by 47% and 73%, respectively. They exhibited morphological defects, including chromatin condensation, vacuolization and haemozoin clumping in both asexual blood-stage and early-stage gametocyte. However, it could not influence the late-stage gametocyte development and gamete formation. Conclusion The inhibition of aspartyl protease by pepstatin A moderately affected both asexual blood-stage and early-stage gametocyte development. Morphological changes on treated parasites implied the effect of pepstatin A on haemoglobin degradation process, suggesting its potential for reducing the severity of the disease and minimizing malaria transmission. However, further research and development are required to use aspartyl protease as a drug target, focusing on identifying and modifying the drug to be more sensitive and effective.
format Article
id doaj-art-5bf6c2b91ff342428d89ba80176c709b
institution Kabale University
issn 1475-2875
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series Malaria Journal
spelling doaj-art-5bf6c2b91ff342428d89ba80176c709b2025-08-24T11:09:18ZengBMCMalaria Journal1475-28752025-08-0124111610.1186/s12936-025-05518-zAspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte developmentGamolthip Niramolyanun0Chonnipa Praikongkatham1Rachaneeporn Jenwithisuk2Wanlapa Roobsoong3Jetsumon Sattabongkot4Viriya Pankao5Niwat Kangwanrangsan6Department of Pathobiology, Faculty of Science, Mahidol UniversityDepartment of Pathobiology, Faculty of Science, Mahidol UniversityMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol UniversityMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol UniversityMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol UniversityDepartment of Preclinical Sciences, Faculty of Medicine, Thammasat UniversityDepartment of Pathobiology, Faculty of Science, Mahidol UniversityAbstract Background Plasmodium falciparum is the most influential species of malaria parasites, capable of causing severe illness and mortality, especially in pregnant women and children under the age of 5. Global distribution of disease impacted on billions of endemic people and travellers. Asexual stage and gametocyte cause harmful manifestations, impacting the patients and contributing to the spread of the disease in the community, respectively. Moreover, most recent therapeutic drugs did not affect the gametocyte. The discovery of a new drug with dual actions on both stages could elucidate a cost-effective way to combat malaria. Within a human host, the parasite possesses many activities for its survival, such as invasion, egress, haemoglobin degradation, and protein trafficking, many of which are related to aspartyl protease, revealing the potential for antimalarial drug targets. Methods Pepstatin A, the representative of the board-spectrum aspartyl protease inhibitor, was utilized to investigate the effects of aspartyl protease inhibition on parasite development. The experiments were separately performed in vitro for different developmental stages of parasites, including the asexual blood-stage, early gametocytes, late gametocytes, and gamete. To demonstrate the effects of pepstatin A, the number of intact parasites and their stage distribution were counted under the microscope and calculated as a percentage of inhibition compared to the control. Additionally, the morphology of pepstatin A-treated parasites was observed to identify cellular alterations in the parasites. Results Pepstatin A at 100 µM inhibited the asexual stage and early-stage gametocyte development by 47% and 73%, respectively. They exhibited morphological defects, including chromatin condensation, vacuolization and haemozoin clumping in both asexual blood-stage and early-stage gametocyte. However, it could not influence the late-stage gametocyte development and gamete formation. Conclusion The inhibition of aspartyl protease by pepstatin A moderately affected both asexual blood-stage and early-stage gametocyte development. Morphological changes on treated parasites implied the effect of pepstatin A on haemoglobin degradation process, suggesting its potential for reducing the severity of the disease and minimizing malaria transmission. However, further research and development are required to use aspartyl protease as a drug target, focusing on identifying and modifying the drug to be more sensitive and effective.https://doi.org/10.1186/s12936-025-05518-zAspartyl proteaseDevelopmental inhibitionGametocyteMalariaTransmission
spellingShingle Gamolthip Niramolyanun
Chonnipa Praikongkatham
Rachaneeporn Jenwithisuk
Wanlapa Roobsoong
Jetsumon Sattabongkot
Viriya Pankao
Niwat Kangwanrangsan
Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development
Malaria Journal
Aspartyl protease
Developmental inhibition
Gametocyte
Malaria
Transmission
title Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development
title_full Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development
title_fullStr Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development
title_full_unstemmed Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development
title_short Aspartyl protease inhibition interferes with Plasmodium falciparum asexual blood-stage and early gametocyte development
title_sort aspartyl protease inhibition interferes with plasmodium falciparum asexual blood stage and early gametocyte development
topic Aspartyl protease
Developmental inhibition
Gametocyte
Malaria
Transmission
url https://doi.org/10.1186/s12936-025-05518-z
work_keys_str_mv AT gamolthipniramolyanun aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment
AT chonnipapraikongkatham aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment
AT rachaneepornjenwithisuk aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment
AT wanlaparoobsoong aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment
AT jetsumonsattabongkot aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment
AT viriyapankao aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment
AT niwatkangwanrangsan aspartylproteaseinhibitioninterfereswithplasmodiumfalciparumasexualbloodstageandearlygametocytedevelopment